GENETICALLY-DETERMINED DRUG-METABOLIZING ACTIVITY AND DESIPRAMINE-ASSOCIATED CARDIOTOXICITY - A CASE-REPORT

被引：26

作者：

BLUHM, RE

WILKINSON, GR

SHELTON, R

BRANCH, RA

机构：

[1] VANDERBILT UNIV,DEPT PSYCHIAT,NASHVILLE,TN 37232

[2] UNIV PITTSBURGH,MED CTR,CTR CLIN PHARMACOL,PITTSBURGH,PA 15260

[3] VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232

来源：

关键词：

D O I：

10.1038/clpt.1993.13

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：89 / 95

页数：7

共 30 条

[1] ARNS PA, 1990, HEPATOLOGY, V12, P977
[2] ARNS PA, IN PRESS CLIN PHARM
[3] THE DEBRISOQUINE HYDROXYLATION TEST PREDICTS STEADY-STATE PLASMA-LEVELS OF DESIPRAMINE
BERTILSSON, L
ABERGWISTEDT, A
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (03) : 388 - 390
[4] TRICYCLIC ANTIDEPRESSANT OVERDOSE - INCIDENCE OF SYMPTOMS
BIGGS, JT
SPIKER, DG
PETIT, JM
ZIEGLER, VE
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1977, 238 (02): : 135 - 138
[5] BLUHM R, 1991, CLIN PHARMACOL THER, V49, P157
[6] ROLE OF P450IID6, THE TARGET OF THE SPARTEINE-DEBRISOQUIN OXIDATION POLYMORPHISM, IN THE METABOLISM OF IMIPRAMINE
BROSEN, K
ZEUGIN, T
MEYER, UA
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (06) : 609 - 617
[7] FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM
BROSEN, K
SKJELBO, E
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (01) : 136 - 137
[8] CARDIOVASCULAR EFFECTS OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS
BURCKHARDT, D
RAEDER, E
MULLER, V
IMHOF, P
NEUBAUER, H
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (03): : 213 - 216
[9] CARR K, 1978, BRIT J CLIN PHARMACO, V6, P421, DOI 10.1111/j.1365-2125.1978.tb04606.x
[10] CRAMMER JL, 1969, PSYCHOPHARMACOLOGIA, V15, P207